沙格列汀对2型糖尿病患者缺血性脑卒中后认知功能的影响

doi:10.3969/j.issn.1006-7795.2019.05.010

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (5): 715-720.doi: 10.3969/j.issn.1006-7795.2019.05.010

• 脑缺血损伤的基础及临床研究 • 上一篇下一篇

沙格列汀对2型糖尿病患者缺血性脑卒中后认知功能的影响

李森¹, 黄安琪², 郭健飞¹, 白洁¹, 张光珍¹, 王婷³, 赵咏梅⁴

1. 聊城市人民医院内分泌科, 山东聊城 252000;
2. 聊城市人民医院神经内科, 山东聊城 252000;
3. 聊城市人民医院中西医结合儿科重点实验室, 山东聊城 252000;
4. 首都医科大学宣武医院神经变性病教育部重点实验室, 北京 100053

收稿日期:2019-07-08 出版日期:2019-09-21 发布日期:2019-12-16
通讯作者: 王婷, 赵咏梅 E-mail:tinawang1003@sina.com;yongmeizhao@hotmail.com
基金资助:
山东省自然科学基金（ZR2017PH054），山东省医药卫生科技发展计划（2017WS327）。

Effect of saxagliptin on cognitive function in patients with type 2 diabetes after ischemic stroke

Li Sen¹, Huang Anqi², Guo Jianfei¹, Bai Jie¹, Zhang Guangzhen¹, Wang Ting³, Zhao Yongmei⁴

1. Department of Endocrinology, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, China;
2. Department of Neurology, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, China;
3. Key Laboratory for Pediatrics of Integrated Traditional and Western Medicine, Liaocheng People's Hospital, Liaocheng 252000, Shandong Province, China;
4. Key Laboratory of Neurodegenerative Disease of Ministry of Education, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Received:2019-07-08 Online:2019-09-21 Published:2019-12-16
Supported by:
This study was supported by Natural Science Foundation of Shandong Province(ZR2017PH054),Shandong Medicine and Health Science Technology Development Project(2017WS327)

摘要/Abstract

摘要： 目的研究沙格列汀干预对缺血性卒中合并2型糖尿病人群认知功能的影响。方法前瞻性队列研究，将255例新发缺血性卒中合并2型糖尿病患者随机分配至沙格列汀组和非沙格列汀组（格列齐特干预），记录基线状态下资料包括人口学特征、生化检验结果等，并使用蒙特利尔认知评估量表（Montreal Cognitive Assessment，MoCA）进行初始认知功能评估，得分<26分及血糖不达标者排除。筛选合格者206例，分别于卒中后1、3、5个月时再次评估，以得分<22分记为终点事件，认为出现卒中后认知障碍（post-stroke cognitive impairment，PSCI）。采用多因素Cox回归分析比较两组患者MoCA得分情况。结果最终130例受试者完成研究，比较两组患者的基线水平资料，差异无统计学意义。观察结束时，沙格列汀组患者共62人纳入分析，其中37人达终点事件，PSCI发生率59.7%，非沙格列汀组共68人纳入分析，其中50人达终点事件，PSCI发生率73.5%。多因素COX回归分析提示，沙格列汀干预的风险比（hazard rate，HR）为0.617，95%CI为0.388~0.983（P<0.05）。结论沙格列汀降糖治疗可减轻缺血性脑卒中合并2型糖尿病患者的PSCI程度。

关键词: 认知功能, 卒中, 卒中后认知障碍, 糖尿病, 沙格列汀

Abstract: Objective To investigate the effect of saxagliptin on cognitive function in patients with ischemic stroke and type 2 diabetes.Methods This is a prospective cohort study. A total of 255 new ischemic stroke patients combined with type 2 diabetes were randomly divided into two groups, saxagliptin group and non-saxagliptin group (intervened with gliclazide). Demographic characteristics and basic biochemistry data were collected. The initial cognitive function was evaluated by Montreal Cognitive Assessment (MoCA). The participants with MoCA score below 26 and/or serum glucose disqualified were excluded. Totally 206 patients were screened, and cognitive function assessment was re-evaluated at 1, 3, and 5 months after stroke. The score below 22 points was set as the end point event, which was defined as post-stroke cognitive impairment (PSCI). MoCA scores between the two groups were analyzed with multivariate COX regression analysis.Results Totally 130 cases complete this research. Baseline data were compared between the two groups and no statistical differences were observed. At the end of the observation, 37 patients in the saxagliptin group reached the end point (62 analyzed), with the incidence of PSCI 59.7%, and 50 patients in the non-saxagliptin group reached the end point (68 analyzed), with the incidence of PSCI 73.5%. Multivariate COX regression analysis suggested that the hazard ratio (HR) for saxagliptin intervention was 0.617, with 95%CI 0.388~0.983 and P<0.05.Conclusion Saxagliptin hypoglycemic therapy can reduce the degree of PSCI in patients with ischemic stroke complicated with type 2 diabetes. Conclusion Saxagliptin hypoglycemic therapy can reduce the degree of PSCI in patients with ischemic stroke complicated with type 2 diabetes.

Key words: cognitive function, stroke, post-stroke cognitive impairment, diabetes, saxagliptin

中图分类号:

李森, 黄安琪, 郭健飞, 白洁, 张光珍, 王婷, 赵咏梅. 沙格列汀对2型糖尿病患者缺血性脑卒中后认知功能的影响[J]. 首都医科大学学报, 2019, 40(5): 715-720.

Li Sen, Huang Anqi, Guo Jianfei, Bai Jie, Zhang Guangzhen, Wang Ting, Zhao Yongmei. Effect of saxagliptin on cognitive function in patients with type 2 diabetes after ischemic stroke[J]. Journal of Capital Medical University, 2019, 40(5): 715-720.

参考文献

[1] Mijajlović M D, Pavlović A, Brainin M, et al. Post-stroke dementia-a comprehensive review[J]. BMC Med, 2017,15(1):11-22.
[2] 董强, 郭起浩, 罗本燕, 等. 卒中后认知障碍管理专家共识[J]. 中国卒中杂志, 2017,12(6):519-531.
[3] Lim J S, Kim C, Oh M S, et al. Effects of glycemic variability and hyperglycemia in acute ischemic stroke on post-stroke cognitive impairments[J]. J Diabetes Complications, 2018,32(7):682-687.
[4] Duarte A I, Candeias E, Correia S C, et al. Crosstalk between diabetes and brain:glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration[J]. Biochim Biophys Acta, 2013,1832(4):527-541.
[5] Hackett M L, Pickles K. Part I:frequency of depression after stroke:an updated systematic review and meta-analysis of observational studies[J]. Int J Stroke, 2014,9(8):1017-1025.
[6] Dichgans M, Leys D. Vascular cognitive impairment[J]. Circ Res, 2017,120(3):573-591.
[7] 黎洁洁, 彭玉晶, 王拥军. 早期二甲双胍治疗对糖尿病前期合并短暂局灶脑缺血后长期认知功能的影响[J]. 中国卒中杂志, 2018,13(8):834-839.
[8] Cimini A, Cerù M P. Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation[J]. Stem Cell Rev, 2008,4(4):293-303.
[9] Zanotto C, Simão F, Gasparin M S, et al. Exendin-4 reverses biochemical and functional alterations in the blood-brain and blood-CSF barriers in diabetic rats[J]. Mol Neurobiol, 2016,54(3):2154-2166.
[10] 虎子颖,张会峰,汪艳芳. 利格列汀对老年2型糖尿病患者轻度认知功能障碍的影响及机制研究[J]. 中华老年医学杂志, 2018,37(10):1069-1072.
[11] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志,2018,10(1):4-67.
[12] 中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
[13] Lees R, Selvarajah J, Fenton C, et al. Test accuracy of cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke[J]. Stroke, 2014,45(10):3008-3018.
[14] Wang Q, Zhao K, Cai Y, et al. Prediabetes is associated with post-stroke cognitive impairment in ischaemic stroke patients[J]. Brain Res, 2018,1687:137-143.
[15] Umarova R M, Sperber C, Kaller C P, et al. Cognitive reserve impacts on disability and cognitive deficits in acute stroke[J]. J Neurol, 2019,June 28. doi:10.1007/S00415-019-09442-6.[Epub ahead of print].
[16] Rhea E M, Banks W A. Role of the blood-brain barrier in central nervous system insulin resistance[J]. Front Neurosci, 2019,13:521-534.
[17] de la Monte S M. Insulin resistance and neurodegeneration:progress towards the development of new therapeutics for alzheimer's disease[J]. Drugs, 2017,77(1):47-65.
[18] Bergmann N C, Lund A, Gasbjerg L S, et al. Effects of combined GIP and GLP-1 infusion onenergy intake, appetite and energy expenditure in overweight/obese individuals:a randomised, crossover study[J]. Diabetologia, 2019,62(4):665-675.
[19] Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction:from physiology to therapeutic perspective[J]. Hum Reprod Update, 2019,25(4):504-517.
[20] Mcclean P L, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease[J]. J Neurosci, 2011,31(17):6587-6594.
[21] Lennox R, Flatt P R, Gault V A. Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice[J]. Peptides, 2014,61:38-47.
[22] Perry T, Lahiri D K, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron[J]. J Neurosci Res, 2003,72(5):603-612.
[23] Nakaoku Y, Saito S, Yamamoto Y, et al. The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in tauopathy model mice[J]. Int J Mol Sci, 2019,20(10):pii:E2539.
[24] Hardigan T, Abdul Y, Ergul A. Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes[J]. Life Sci, 2016,159:90-96.
[25] Gault V A, Lennox R, Flatt P R. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline[J]. Diabetes Obes Metab, 2015,17(4):403-413.

沙格列汀对2型糖尿病患者缺血性脑卒中后认知功能的影响

Effect of saxagliptin on cognitive function in patients with type 2 diabetes after ischemic stroke

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李琼, 赵建华, 刘昊, 王凡, 李青, 陈希妍, 蔡瑞艳, 吴清武, 张健, 吉四辈, 路承彪, 李少敏. 脑白质高信号患者血清CX3CL1水平与认知功能障碍的关系[J]. 首都医科大学学报, 2023, 44(1): 6-12.
[2]	徐建可, 刘宁, 韩苗, 张洪阳, 韩新生. 缺血性脑卒中患者颈动脉斑块性质与非高密度脂蛋白胆固醇浓度的相关性[J]. 首都医科大学学报, 2023, 44(1): 49-53.
[3]	秦琳慧, 李宁, 杨宇, 杨勇, 任长虹. 肢体远隔缺血期适应联合后适应促进大鼠缺血性脑卒中模型神经发生的作用及机制[J]. 首都医科大学学报, 2023, 44(1): 54-61.
[4]	李雪, 范俊芬, 王荣亮, 马青峰, 罗玉敏, 赵海苹. HDAC2对急性缺血性卒中患者中性粒细胞TBC蛋白家族成员的表观调控[J]. 首都医科大学学报, 2023, 44(1): 62-71.
[5]	姜富城, 黄菊梅, 冯跃先, 钟红亮, 贾建文, 杨洪超, 刘赫, 刘扬. 清醒镇静在急性缺血性脑卒中血管内治疗中的应用效果及预后影响评估[J]. 首都医科大学学报, 2023, 44(1): 72-77.
[6]	李森, 郭学文, 赵鑫, 黄安琪, 林婧格, 李兴茂, 李秀, 杜怡峰, 赵咏梅, 白洁, 夏章勇. 急性缺血性脑卒中合并糖尿病人群的血糖变异性与神经功能恶化的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 78-84.
[7]	苏志燕, 刘薇, 史婷婷. 老年2型糖尿病患者血尿酸浓度与代谢综合征的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 137-142.
[8]	赵继宗. 我国脑心血管共患疾病现状与临床研究[J]. 首都医科大学学报, 2022, 43(5): 671-673.
[9]	黄琪, 周亦伦, 孙雪峰. 共享外周循环对糖尿病肾病小鼠肾损伤的影响[J]. 首都医科大学学报, 2022, 43(5): 674-679.
[10]	王梦迪, 郭弋凡, 庞彦余, 刘羽飞, 赵文景. 保肾通络方含药血清调节线粒体自噬对高糖诱导下足细胞氧化损伤的影响[J]. 首都医科大学学报, 2022, 43(5): 687-693.
[11]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[12]	马艺欣, 张仲迎, 佀思聪, 罗鸿宇, 赵欢, 杨伟. 2型糖尿病患者新型脂肪因子血清内脏脂肪素和内脏脂肪特异性丝氨酸蛋白酶抑制因子的表达水平与左心室肥厚的关系[J]. 首都医科大学学报, 2022, 43(5): 767-773.
[13]	安宇, 边南南, 丁小雨, 常晓娜, 刘佳, 王广. 1型糖尿病伴认知功能损伤小鼠脑组织肠道菌群代谢物的改变[J]. 首都医科大学学报, 2022, 43(4): 622-629.
[14]	修双玲, 付俊玲, 穆志静, 孙丽娜, 赵蕾. 老年2型糖尿病患者体脂率对肌力和躯体功能的影响[J]. 首都医科大学学报, 2022, 43(4): 641-646.
[15]	许新, 阮祥燕, 鞠蕊, 杨瑜, 程姣姣, 王志坤, Alfred O. Mueck. 中国女性轻度认知障碍的影响因素及其与绝经症状的关系[J]. 首都医科大学学报, 2022, 43(3): 369-374.